Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will present on Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST).
Investors and interested parties can access the live audio webcast, presentation slides, and event replay through the Events and Presentations section of the company's website at www.enovis.com.
Enovis (NYSE: ENOV) has announced its management team's participation in two upcoming investor conferences. At the Jefferies London Healthcare Conference, Chair and CEO Matt Trerotola and CFO Ben Berry will join a fireside chat on November 20th at 12:00 p.m. GMT. Subsequently, CFO Ben Berry will participate in the Evercore 7th Annual HealthCONx Conference on December 4th at 10:50 a.m. ET.
Both events will be available via live audio webcasts and replays on the company's website under the Investors tab. Enovis is a medical technology growth company focused on developing clinically differentiated solutions for better patient outcomes and workflow transformation in orthopedics and beyond.
Enovis (ENOV) reported third-quarter 2024 results with net sales of $505 million, showing 21% growth on a reported basis and 6% on a comparable basis. The company's Reconstructive segment grew 57% reported (9% comparable), while P&R grew 1% reported (3% comparable). Despite reporting a net loss from continuing operations of $34 million ($0.61 per share), adjusted earnings were $0.73 per share, up 30% Y/Y. Adjusted EBITDA reached $90 million or 17.9% of sales. The company narrowed its 2024 revenue guidance to $2.10 billion and adjusted EBITDA to $373-$378 million, while raising full-year adjusted EPS guidance to $2.75-$2.80.
Enovis (NYSE: ENOV), a medical technology growth company, has announced it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time. The company will issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.
Investors can access the live webcast via a link on the Enovis website. Those planning to participate on the call should dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A replay of the call will be available on the Enovis website later that day.
Enovis (NYSE: ENOV) has appointed Tim Czartoski as President of U.S. Surgical and Global Product and Enabling Technologies. Czartoski, who reports to Louie Vogt, Group President of Enovis' Reconstructive Business Group, brings over 22 years of experience from Depuy Synthes, Johnson & Johnson's Orthopaedics Company. In his previous role, he led Depuy Synthes' U.S. operations, overseeing joint reconstruction, trauma, spine, digital technology, capital, sports, and CMF businesses.
Czartoski's appointment is expected to accelerate Enovis' growth potential and strengthen its surgical pipeline globally. His educational background includes a B.S. from Ohio State University, an M.S. in Technology Management from Columbia, and an MBA from Notre Dame.
Enovis™ (NYSE: ENOV), a medical technology company, is set to unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting from September 11–14, 2024, in Vancouver. The Tarsoplasty system aims to reduce operative time and improve patient recovery outcomes for bunionectomy procedures. Better Step enhances the patient experience throughout bunion surgery recovery. Enovis will also showcase other advanced solutions, including the DynaNail® TTC Fusion System, Evolve34™ Lapidus Correction System, and expanded options for the Arsenal Foot Plating System.
Enovis (NYSE: ENOV) has expanded its EMPOWR Revision Knee™ system with the addition of EMPOWR™ Cones, creating a comprehensive portfolio for complex revision knee surgeries. The FDA-cleared cones include stackable tibial, femoral, and diaphyseal options to treat bone defects. This expansion aims to redefine revision knee arthroplasty by offering a streamlined yet comprehensive setup, reducing operating room clutter while allowing surgeons to fine-tune implant fit.
The system's features include femoral and tibial stackable augments usable both medially and laterally, minimizing excess inventory. Multifunctional instrumentation keeps the surgeon's back table organized, streamlining procedures. The addition of EMPOWR Cones provides surgeons with greater flexibility in tailoring revision surgeries, addressing a market need for more efficient revision options, particularly with growing interest in outpatient procedures.
Enovis (NYSE: ENOV) has introduced the STAR® Ankle with new e+™ Polyethylene, following FDA approval. This makes it the first and only mobile bearing ankle system with e+™ Polyethylene in the United States. The implant's vitamin E-blended insert offers improved durability, stability, and longevity.
Key features of e+™ Polyethylene include:
- Resistance to oxidation
- Consistent wear rates
- Stable mechanical properties over time
The STAR® Ankle has been used globally over 40,000 times across its 37-year history. This innovation, combined with the recent release of STAR Patient Specific Instrumentation (PSI), represents Enovis' commitment to enhancing patient satisfaction and outcomes in foot and ankle solutions.
Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in three upcoming investor conferences:
- Canaccord Genuity 44th Annual Growth Conference on August 13th
- Wells Fargo Healthcare Conference on September 5th
- Baird 2024 Global Healthcare Conference on September 11th
The company's management team, including CFO Ben Berry and CEO Matt Trerotola, will participate in fireside chats at these events. Live audio webcasts and replays will be available on Enovis' website under the Investors tab. Enovis is dedicated to developing clinically differentiated solutions for better patient outcomes and improved workflows in orthopedics and beyond.
Enovis (NYSE: ENOV) reported strong Q2 2024 results with 23% sales growth to $525 million and adjusted EBITDA margin expansion of 190 basis points to 17.2%. The company saw 60% reported growth in Recon and 2% in P&R. Despite a net loss of $0.34 per share, adjusted earnings were $0.62 per share. Enovis received FDA clearances for Arvis 2.0 Shoulder and Altivate Reverse Glenoid system, opened a Business Technology Center in Lisbon, and a new manufacturing facility in San Daniele. The company narrowed its 2024 revenue guidance to $2.08-$2.13 billion, reaffirmed adjusted EBITDA expectations of $368-$383 million, and raised adjusted EPS guidance to $2.62-$2.77.